Over the past few years, ICIs, including both anti-PD-1 and anti-PD-L1 antibodies, have shown favorable efficacy in both advanced non-small-cell lung cancer (NSCLC) and extensive-stage small-cell lung cancer (SCLC) [6,7]. Here, CD274 is linked to small cell lung carcinoma.